Estrogen modulation of avian osteoclast lysosomal gene expression.

We have previously demonstrated that avian osteoclasts contain high levels of 17 beta-estradiol (17 beta E2) receptors and respond to 17 beta E2 treatment with a dose-dependent decrease in in vitro resorption of [3H] proline-labeled bone particles. To more accurately assess the influence of 17 beta E2 on osteoclastic activity, the specificity of estrogen modulation of resorption levels was determined using a quantitative pit resorption assay. Treatment with 17 beta E2 significantly decreased the number of osteoclast resorption pits formed compared with that after either vehicle or 17 alpha E2 treatment. Cotreatment with 17 beta E2 and hydroxytamoxifen (a complete 17 beta E2 antagonist in birds) abrogated the influence of 17 beta E2 on resorption activity. To elucidate the mechanism by which 17 beta E2 inhibits osteoclast activity, the effects of 17 beta E2 on the steady state mRNA levels of two avian osteoclast lysosomal proteins, lysozyme and a lysosomal membrane protein (LEP-100), were examined. Using highly purified avian osteoclasts, 17 beta E2 was shown to decrease lysosomal protein mRNA levels in a dose-dependent manner within 8 h of treatment in a process that required de novo protein synthesis. This response was specific for 17 beta E2, since the inactive stereoisomer 17 alpha E2 had no effect. Furthermore, coincubation of 17 beta E2 with hydroxytamoxifen eliminated the 17 beta E2 influence. After removal of 10(-8) M 17 beta E2, lysosomal gene mRNA levels returned to near-normal levels within 24 h. This is consistent with the previously reported ability of avian osteoclast-mediated resorption activity to recover from 17 beta E2 treatment. Lysozyme protein levels similarly decreased after 17 beta E2 treatment. These data suggest that avian osteoclasts are target cells for 17 beta E2 in vitro, that osteoclast activity in vivo is likely to be modulated by circulating levels of 17 beta E2, and that the 17 beta E2 inhibition of osteoclast resorption activity may be mediated at least in part via regulation of osteoclast lysosomal gene expression.

[1]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6 , 1992 .

[2]  B. Riggs,et al.  Modulation of Transforming Growth Factor-β Production in Normal Human Osteoblast-Like Cells by 17β-Estradiol and Parathyroid Hormone , 1991 .

[3]  M. Oursler,et al.  Osteoclast‐specific monoclonal antibodies coupled to magnetic beads provide a rapid and efficient method of purifying avian osteoclasts , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  B. Riggs,et al.  Avian osteoclasts as estrogen target cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Oursler,et al.  Isolation of avian osteoclasts: Improved techniques to preferentially purify viable cells , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  B. Riggs,et al.  Lack of a direct effect of estrogen on proliferation and differentiation of normal human osteoblast‐like cells , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  D. Dempster,et al.  The effects of parathyroid hormone (PTH) and PTH-related peptide on osteoclast resorption of bone slices in vitro: an analysis of pit size and the resorption focus. , 1990, Endocrinology.

[8]  A. Kahn,et al.  Lysozyme synthesis in osteoclasts , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  R. Baron,et al.  Selective internalization of the apical plasma membrane and rapid redistribution of lysosomal enzymes and mannose 6-phosphate receptors during osteoclast inactivation by calcitonin. , 1990, Journal of cell science.

[10]  M. Korc,et al.  Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. , 1990, Cancer research.

[11]  G. Mundy,et al.  Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. , 1988, The Journal of clinical investigation.

[12]  Kenneth G. Mann,et al.  Evidence of estrogen receptors in normal human osteoblast-like cells , 1988 .

[13]  G. Vaes.  Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. , 1988, Clinical orthopaedics and related research.

[14]  K. Takeyasu,et al.  Structure of LEP100, a glycoprotein that shuttles between lysosomes and the plasma membrane, deduced from the nucleotide sequence of the encoding cDNA , 1988, The Journal of cell biology.

[15]  R. Derynck,et al.  Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Avioli.  Calcium and osteoporosis. , 1984, Annual review of nutrition.

[17]  D. Feldman,et al.  Distinction between alpha-fetoprotein and intracellular estrogen receptors: evidence against the presence of estradiol receptors in rat bone. , 1978, Endocrinology.